Patients With Psoriatic Arthritis–Related Enthesitis and Persistence on Tofacitinib Under Real-World Conditions

Ignacio Braña; Marta Loredo; Estefanía Pardo; Stefanie Burger; Eva Fernández-Bretón; Rubén Queiro

doi:10.3899/jrheum.2024-0016

Article Figures & Data

Figures

Tables
Additional Files

Download figure
Open in new tab
Download powerpoint
Figure 1.
Kaplan-Meier curve of all-cause discontinuation of tofacitinib.
Download figure
Open in new tab
Download powerpoint
Figure 2.
Kaplan-Meier survival curve stratified by enthesitis.

View popup

Table.

Disease characteristics of the study population.

	Women, n = 54	Men, n = 18	Total, n = 72
Age, yrs, mean (SD)	51.8 (10.5)	52.1 (13.0)	51.9 (11.1)
Psoriasis duration, yrs, mean (SD)	16.4 (11.9)	15.2 (7.79)	16.1 (11.0)
PsA duration, yrs, mean (SD)	10.3 (7.51)	10.8 (5.36)	10.4 (6.99)
Weight, kg, mean (SD)	75.3 (18.1)	83.1 (14.0)	77.7 (17.3)
Hypertension	17 (31.5)	5 (27.8)	22 (30.6)
Dyslipidemia	16 (29.6)	3 (16.7)	19 (26.4)
Diabetes	5 (9.3)	2 (11.1)	7 (9.7)
Current smoker	16 (29.6)	3 (16.7)	19 (26.4)
Former smoker	16 (29.6)	3 (16.7)	19 (26.4)
Joint pattern
Peripheral	38 (70.4)	10 (55.6)	48 (66.7)
Axial	3 (5.6)	0 (0)	3 (4.2)
Mixed	13 (24.1)	8 (44.4)	21 (29.2)
Plaque psoriasis	32 (59.3)	16 (88.9)	48 (66.7)
Nail disease	18 (33.3)	10 (55.6)	28 (38.9)
Dactylitis	13 (24.1)	7 (38.9)	20 (27.8)
Enthesitis	11 (20.4)	4 (22.2)	15 (20.8)
Depression	36 (66.7)	4 (22.2)	40 (55.6)
Prior b/tsDMARDs	53 (98.1)	18 (100)	71 (98.6)
Adalimumab	45 (83.3)	17 (94.4)	62 (87.3)
Etanercept	25 (46.3)	12 (66.7)	37 (52.1)
Golimumab	17 (31.5)	7 (38.9)	24 (33.8)
Infliximab	12 (22.2)	8 (44.4)	20 (28.2)
Certolizumab	2 (3.7)	0 (0)	2 (2.8)
Ixekizumab	30 (55.6)	9 (50.0)	39 (54.9)
Secukinumab	13 (24.1)	5 (27.8)	18 (25.4)
Ustekinumab	16 (29.6)	4 (22.2)	20 (28.2)
Apremilast	8 (14.8)	2 (11.1)	10 (14.1)
TOF line
1	1 (1.9)	0 (0)	1 (1.4)
2	17 (31.5)	1 (5.6)	18 (25.0)
3	11 (20.4)	8 (44.4)	19 (26.4)
4	13 (24.1)	5 (27.8)	18 (25.0)
≥ 5	12 (22.2)	4 (22.2)	16 (22.2)
TOF current intake^{^a}
Yes	19 (35.2)	8 (44.4)	27 (37.5)
No	35 (64.8)	10 (55.6)	45 (62.5)
Median treatment exposure, mos^{^a} (min, max)	7.44 (0.23, 42.8)	14.7 (0, 40.0)	10.0 (0, 42.8)
DAPSA^{^a}, mean (SD)	14.2 (7.9)	9.2 (6.1)	12.4 (6.5)
PsAID^{^a}, mean (SD)	4.1 (2.2)	3.6 (3.2)	3.7 (3.3)

Values are expressed as n (%) unless indicated otherwise.
↵^a Values collected at the end of the study (database closure). PsA: psoriatic arthritis; b/tsDMARD: biologic/targeted synthetic disease-modifying antirheumatic drug; min: minimum; max: maximum; DAPSA: Disease Activity Index for Psoriatic Arthritis; PsAID: Psoriatic Arthritis Impact of Disease; TOF: tofacitinib.